Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $115.9M
!
Reach your audience today.

Corporate Spotlight
Last update - 16.10pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 4.9¢ | Day High | 5.2¢ | Day Low | 4.9¢ | |||
| Daily Volume | 18031287 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 4.8¢ | 2494333 | 0 | 4.9¢ | 183492 | |
Directors & Senior Management
| Mr. David Dickson | MD, CEO & Director |
| Mr. Geoffrey Stuart Crow | Non-Executive Chairman of the Board |
| Mr. Justin Olson | Chief Legal, Compliance & Risk Officer and General Counsel |
| Mr. L Don Miller | Chief Financial Officer |
| Ms. Lindsay R. Bourg | Chief Accounting Officer |
| Ms. Nkechi Ezimah | Senior Finance Manager & Company Secretary |
| Dr. Robert Trzebski | Independent Non-Executive Director |
| Mr. Stephen Promnitz | Managing Director |
Data source: ADVFN
